{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016870","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.063293+00:00","generated_at":"2026-06-24T01:01:02.656590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ORIC reports Q2 2022 cash $237.8M; three Phase 1 readouts expected 1H 2023","bullets":["Cash and investments $237.8M as of June 30, 2022; funds operations into 2H 2024.","R&D expenses $13.8M for Q2 2022, down from $15.5M in Q2 2021, mainly on lower ORIC-101 costs.","G&A expenses $6.9M for Q2 2022, up from $5.5M in Q2 2021, due to higher personnel costs.","Three ongoing Phase 1 programs (ORIC-533, ORIC-114, ORIC-944) with initial data expected 1H 2023.","Preclinical data on PLK4 inhibitor program presented at AACR in April 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016870","json":"https://secwatch.observer/filing/0000950170-22-016870.json","markdown":"https://secwatch.observer/filing/0000950170-22-016870.md","text":"https://secwatch.observer/filing/0000950170-22-016870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/0000950170-22-016870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/oric-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:01:02.656590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}